Update
Zealand Pharma Partners with Generate Biomedicines for Obesity Drug Collaboration
Zealand Pharma has entered a multi-target collaboration and license agreement with Generate Biomedicines, a biotech company that went public in February 2026. The collaboration could potentially reach up to $1.2 billion in total milestone payments, including $30 million upfront and tiered royalties based on net sales. Generate’s platform combines AI-driven protein design with experimental validation, aiming to develop multispecific protein therapeutics for complex conditions like obesity. Zealand will assume responsibility for clinical development and commercialization of any resulting therapeutics.